Mirtazapine inhibits tumor growth via immune response and serotonergic system

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Fang, Chun Kai ^a,b   Chen, Hong Wen ^b   Chiang, I Tsang ^a   Chen, Chia Chieh ^c   Liao, Jyh Fei ^a   Su, Ton Ping ^d   Tung, Chieh Yin ^a   Uchitomi, Yosuke ^e   Hwang, Jeng Jong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; MIRTAZAPINE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONTROLLED STUDY; EX VIVO STUDY; IMMUNOCOMPETENCE; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEROTONINERGIC SYSTEM; SURVIVAL RATE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; WILD TYPE;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; AUTORADIOGRAPHY; COLONIC NEOPLASMS; GENES, REPORTER; IMMUNITY, INNATE; IMMUNOCOMPROMISED HOST; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; INTERLEUKIN-12; LUCIFERASES; MALE; MIANSERIN; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM TRANSPLANTATION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS;

EID: 84863772430     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038886     Document Type: Article

References (50)

1. Miovic M, Block S, (2007) Psychiatric disorders in advanced cancer. Cancer 110: 1665-1676.
2. Xu W, Tamim H, Shapiro S, Stang MR, Collet JP, (2006) Use of antidepressants and risk of colorectal cancer: A nested case-control study. Lancet Oncol 7: 301-308.
3. Abdul M, Logothetis CJ, Hoosein NM, (1995) Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154: 247-250.
4. Rosetti M, Frasnelli M, Tesei A, Zoli W, Conti M, (2006) Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. J Exp Ther Oncol 6: 23-29.
5. Pan CC, Cheng HH, Huang CJ, Lu YC, Chen IS, et al. (2006) The antidepressant mirtazapine-induced cytosolic Ca2+ elevation and cytotoxicity in human osteosarcoma cells. Chin. J. Physiol 49: 290-297.
6. Gil-Ad I, Zolokov A, Lomnitski L, Taler M, Bar M, et al. (2008) Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol 33: 277-286.
7. Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, et al. (2007) Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol 8: 603-612.
8. Lutgendorf SK, Sood AK, Antoni MH, (2010) Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncl 28: 4094-4099.
9. Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, et al. (2011) Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res 17: 3649-3659.
10. Kim YK, Suh IB, Kim H, Han CS, Lim CS, et al. (2002) The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs. Mol Psychiatry 7: 1107-1114.
11. Lee KM, Kim YK, (2006) The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 6: 1298-1304.
12. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, et al. (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230.
13. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, et al. (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87: 581-586.
14. Kast RE, (2001) Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 9: 469-470.
15. Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD, (2002) An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 23: 442-447.
16. Kast RE, Foley KF, (2007) Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care 16: 351-354.
17. Cankurtaran ES, Ozalp E, Soygur H, Akbiyik D, Turhan L, et al. (2008) Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer 16: 1291-1298.
18. Kim SW, Shin IS, Kim JM, Kim YC, Kim KS, et al. (2008) Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 62: 75-83.
19. Anttila SA, Leinonen EV, (2001) A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7: 249-264.
20. Marek GJ, Carpenter LL, McDougle CJ, Price LH, (2003) Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28: 402-412.
21. Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C, (2010) Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hospice Paliat Med 27: 106-110.
22. Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD, (2002) An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 23: 442-447.
23. Reich M, (2008) Depression and cancer: Recent data on clinical issues, research challenges and treatment approaches. Curr Opin Oncol 20: 353-359.
24. Steru L, Chermat R, Thierry B, Simon P, (1985) A new method for screening antidepressants in mice. Psychopharmacology 85, 367-370.
25. Kenis G, Maes M, (2002) Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 5: 401-412.
26. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, et al. (2007) Pro- and anti-inflammatory cytokine balance in major depression: Effect of sertraline therapy. Clin Dev Immunol 2007: 76396.
27. De Berardis D, Conti CM, Serroni N, Moschetta FS, Olivieri L, et al. (2010) The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 23: 417-422.
28. Lopez MC, Stanley MA, (2000) Cytokine profile of draining lymph node lymphocytes in mice grafted with syngeneic keratinocytes expressing human papillomavirus type 16 E7 protein. J Gen Virol 81: 1175-1182.
29. Gu T, Roswell-Turner RB, Kilinc MO, Egilmez NK, (2010) Central role of IFN-γ-indoleamine 2, 3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res 70: 129-138.
30. Rakhit A, Yeon MM, Ferrante J, Fettner S, Nadeau R, et al. (1999) Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Clin Pharmacol Ther 65: 615-629.
31. Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, et al. (2000) Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res 60: 3559-3568.
32. Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, et al. (1999) Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20: 370-379.
33. Szuster-Ciesielska A, Tustanowska-Stachura A, Slotwinska M, Marmurowska-Michalowska H, Kandefer-Szerszen M, (2003) In vitro immunoregulatory effects of antidepressants in healthy volunteers. Pol J Pharmacol 55: 353-362.
34. Frick LR, Palumbo ML, Zappia MP, Brocco MA, Cremaschi GA, et al. (2008) Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T-cell response by serotonin-dependent and independent mechanisms. Biochem. Pharmacol 75: 1817-1826.
35. Arimochi H, Morita K, (2006) Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol 541: 17-23.
36. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, et al. (2002) Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 35: 220-225 (in German).
37. Kubera M, Roman A, Basta-Kaim A, Budziszewska B, Zajicova A, et al. (2006) Effect of acute and repeated treatment with mirtazapine on the immunity of noradrenaline transporter knockout C57BL/6J mice. Pharmacol Biochem Behav 85: 813-819.
38. Trinchieri G, (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
39. Heyes MP, Chen CY, Major EO, Saito K, (1997) Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 326: 351-356.
40. Müller N, Schwarz MJ, (2007) Immunological aspects of depressive disorders. Nervenarzt 78: 1261-1273 (in German).
41. Lin KJ, Ye XX, Yen TC, Wey SP, Tzen KY, et al. (2002) Biodistribution study of [123I]ADAM in mice: correlation with whole body autoradiography. Nucl Med Biol 29: 643-650.
42. Lin KJ, Yen TC, Wey SP, Hwang JJ, Ye XX, et al. (2004) Characterization of the binding sites for 123I-ADAM and the relationship to the serotonin transporter in rat and mouse brains using quantitative autoradiography. J Nucl Med 45: 673-681.
43. Tsai HC, Yeh TL, Hsieh MH, Lee IH, Chen KC, et al. (2009) Association between serotonin transporter availability and overall rating scores of quality of life in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry 33: 711-714.
44. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, et al. (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10: 865-871.
45. Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, et al. (2009) Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J Nucl Med 50: 2073-2081.
46. Dazzi L, Ladu S, Spiga F, Vacca G, Rivano A, et al. (2002) Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats. Synapse 43: 70-77.
47. Rogóz Z, Skuza G, Legutko B, (2005) Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol 56: 661-671.
48. Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, et al. (2008) Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol 35: 623-634.
49. Qi H, Ma J, Liu YM, Yang L, Peng L, et al. (2009) Allostatic tumor-burden induces depression-associated changes in hepatoma-bearing mice. J Neurooncol 94: 367-372.
50. Cryan JF, Mombereau C, Vassout A, (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 29: 571-625.